FDA approves first RSV vaccine for at-risk adults in their 50s CBS NewsUS FDA expands GSK’s RSV vaccine approval to adults aged 50 to 59 ReutersFDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach CNBCGSK exec lauds ‘great start’ to RSV vaccine uptake as Arexvy nabs label expansion in adults 50-59 FiercePharmaGSK’s RSV vaccine receives expanded FDA approval STAT